- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Bio-Path Holdings, Sunshine Biopharma, INVO Bioscience among healthcare movers | 3 | Seeking Alpha | ||
| 19.04. | INVO Bioscience, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.04. | INVO Bioscience, Inc. - 10-K/A, Annual Report | 4 | SEC Filings | ||
| 17.04. | Why Invo BioScience Stock Is Soaring Today | 9 | Benzinga.com | ||
| 17.04. | Why Is Invo Bioscience (INVO) Stock Up 85% Today? | 14 | InvestorPlace | ||
| 17.04. | Pre-market Movers: INVO Bioscience, iLearningEngines, Vanda Pharmaceuticals, CXApp, Chromocell Therapeutics | 326 | AFX News | LOWELL (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.45 A.M. ET).In the Green INVO Bioscience, Inc. (INVO) is up over 73% at $1.35.
Vanda... ► Artikel lesen | |
| 17.04. | Why INVO Bioscience Shares Are Trading Higher By Around 73%; Here Are 20 Stocks Moving Premarket | 4 | Benzinga.com | ||
| 16.04. | INVO BioScience reports Q4 results | 4 | Seeking Alpha | ||
| 16.04. | INVO Bioscience: INVO Reports Fourth Quarter and Full Year 2023 Financial Results | 111 | GlobeNewswire (Europe) | SARASOTA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment... ► Artikel lesen | |
| 16.04. | INVO Bioscience, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 11.04. | INVO Bioscience, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.04. | INVO Bioscience, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
| 27.03. | INVO Bioscience, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
| 01.03. | INVO Bioscience, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.02. | INVO Bioscience, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.01. | INVO Bioscience, Inc. - S-4, Registration of securities, business combinations | 1 | SEC Filings | ||
| 10.01. | INVO Bioscience, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.12.23 | INVO Bioscience, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.12.23 | INVO Bioscience, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.11.23 | INVO Bioscience, Inc. - 8-K, Current Report | 2 | SEC Filings |
Seite:
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTUITIVE SURGICAL | 347,90 | -0,80 % | Aktienmarkt: Aktie von Intuitive Surgical tritt auf der Stelle (344,5759 €) | CODE Zuletzt zahlten Investoren für das Papier 366,77 US-Dollar. Die Wertschätzung der privaten und institutionellen Investoren für der Anteilsschein von Intuitive Surgical hat sich heute kaum verändert.... ► Artikel lesen | |
| ROKU | 54,62 | +3,74 % | Roku: Wachstum beschleunigt sich, Verluste weiter reduziert | SAN JOSE, Kalifornien (IT-Times) - Roku, Anbieter von Hard- und Software für Video-Streaming-Services, hat seine Ergebnisse für das Auftaktquartal 2024 veröffentlicht und ein zweistelliges Wachstum... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 1,444 | +1,26 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen | SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company") today announced an expanded research agreement with Weill Cornell Medicine to explore... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 | -- Third Consecutive Year of Phexxi Net Sales Growth --
-- Total Operating Expense Reduced 64% from 2022 Levels --
-- Sales and marketing expense as a percentage of net sales was 54% for the fourth... ► Artikel lesen | |
| CO-DIAGNOSTICS | 1,030 | -0,96 % | Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results | SALT LAKE CITY, March 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic... ► Artikel lesen | |
| QUIDELORTHO | 37,000 | -0,54 % | QuidelOrtho Corp - 8-K, Current Report | ||
| TEMPEST THERAPEUTICS | 3,424 | +3,76 % | Tempest Therapeutics: Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics... ► Artikel lesen | |
| VERU | 1,150 | -2,71 % | Veru Inc.: Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11 | ||
| CENTENE | 68,40 | -1,10 % | Centene-Aktie legt um 0,84 Prozent zu (71,0929 €) | Im Plus liegt aktuell das Wertpapier von Centene . Das Papier kostete zuletzt 75,78 US-Dollar. Heute hat sich an der US-amerikanischen Börse die Centene-Aktie zwischenzeitlich um 0,84 Prozent verteuert.... ► Artikel lesen | |
| IMAGIN MEDICAL | 0,001 | 0,00 % | XFRA DPD3: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILIMAGIN MEDICAL INC.... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 1,580 | +6,04 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results | SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout... ► Artikel lesen | |
| LANTHEUS | 62,62 | +2,15 % | Factors Setting the Tone For Lantheus' (LNTH) Q1 Earnings | ||
| OMNICELL | 25,400 | -3,05 % | Omnicell Announces Fiscal Year and Fourth Quarter 2023 Results | FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy care delivery model, today... ► Artikel lesen | |
| AMN HEALTHCARE SERVICES | 54,00 | +2,86 % | AMN Healthcare Services Inc: Survey: Physicians Turning to Locum Tenens to Improve Work Conditions, Relieve Burnout | ||
| INTELLIGENT BIO SOLUTIONS | 3,870 | 0,00 % | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results | NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen |
INVO BIOSCIENCE INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 1,060 Euro und damit +7,07 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
